Arcutis Biotherapeutics Inc. (ARQT) News
Filter ARQT News Items
ARQT News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
ARQT News Highlights
- For ARQT, its 30 day story count is now at 8.
- Over the past 13 days, the trend for ARQT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ARQT are AMP, LI and DRUG.
Latest ARQT News From Around the Web
Below are the latest news stories about ARCUTIS BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ARQT as an investment opportunity.
The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 TherapeuticsAllogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics are part of the Zacks top Analyst Blog. |
3 Under-$10 Drug Stocks Wall Street Analysts Recommend BuyingWe present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market. |
11 High Growth Micro-Cap Stocks to BuyIn this article, we discuss 11 high-growth micro-cap stocks to buy. To skip the detailed analysis and past performance of micro-cap stocks, go directly to the 5 High Growth Micro-cap Stocks to Buy. Shares of small companies with market capitalization usually between $50 to $300 million are considered micro-cap stocks. The risk in these investments […] |
Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic DermatitisThe FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning! |
Arcutis shares jump after FDA approves drug for chronic skin conditionInvesting.com -- Shares in Arcutis Biotherapeutics (NASDAQ:ARQT) surged on Monday after the U.S. Food and Drug Administration approved the use of the drugmaker's treatment for a skin condition called seborrheic dermatitis in patients nine years of age or older. |
Arcutis shares rally in after-hours trading on FDA approvalMore on Arcutis Biotherapeutics |
UPDATE 3-US FDA approves Arcutis' drug to treat chronic skin diseaseThe U.S. Food and Drug Administration (FDA) on Friday approved Arcutis Biotherapeutics' drug for treating a skin condition called seborrheic dermatitis in individuals nine years of age and older. The health regulator's nod makes roflumilast foam the first topical drug for treating moderate to severe seborrheic dermatitis with a new mechanism of action in over two decades, according to the company. Seborrheic dermatitis, a common, chronic and recurrent inflammatory skin disease, affects more than 10 million people in the U.S., Arcutis said. |
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and OlderZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration of useZORYVE foam provides rapid disease clearance and significant reduction in itch, one of the most burdensome symptoms of seborrheic dermatitisFirst drug approved for seborrheic dermatitis with a new mechanism of action in over two decadesSeborrheic dermatitis affects more than 10 million people i |
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 90,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 106,500 shares of Arcutis’ common stock to 7 newly hired employees. These awards were approved by the Compensation Committee of |